Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

1-3 of 3

• 

  RestartResume

  Integrating EPA-based therapy in the management of residual CV risk

  RestartResume

  Integrating EPA-based therapy in the management of residual CV risk

  Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

  Integrating EPA-based therapy in the management of residual CV risk

  Prof. Ph. Gabriel Steg, MD

  • 

    

    Prof. Ph. Gabriel Steg, MD

• 

  RestartResume

  What is the evidence of EPA-based therapy for CV prevention?

  RestartResume

  What is the evidence of EPA-based therapy for CV prevention?

  Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

  What is the evidence of EPA-based therapy for CV prevention?

  Prof. Lale Tokgözoğlu, MD

  • 

    

    Prof. Lale Tokgözoğlu, MD

• 

  RestartResume

  Unravelling the triglyceride story

  RestartResume

  Unravelling the triglyceride story

  Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

  Unravelling the triglyceride story

  prof. Paul Ridker, MD

  • 

    

    prof. Paul Ridker, MD